Myriad Genetics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Myriad Genetics Inc 's ROA in the second quarter of 2026?
Myriad Genetics Inc recorded a cumulative net loss of $-113 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -16.38%.

However, within the Healthcare sector 343 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4005, from total ROA ranking in the first quarter of 2026 at 4563.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-5.21 %	-33.04 %	-27.39 %	-28.99 %	-34.29 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-113	-400	-366	-401	-395
Return On Assets (TTM)	-16.38 %	-57.42 %	-46.94 %	-47.33 %	-42.93 %
MYGN's Total Ranking	# 4005	# 4563	# 3990	# 3973	# 3303
Total Assets (TTM) in million	642	674	707	728	677
Seq. Total Assets Change	-4.71 %	-4.66 %	-2.95 %	7.5 %	-32.68 %
Seq. Net Income Change	-	-	-	-	-

MYGN's 5 Years Annual ROA >> Back to MYGN Management Effectiveness >> Compare MYGN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 4
Sector	# 344
Overall	# 3352

Return On Assets Statistics
High	Average	Low
24.09 %	-1.54 %	-57.42 %
(Dec 31 2013)		(Mar 31 2026)

News about Myriad Genetics Inc Return on Assets ROA

Myriad Genetics Announces Leadership Transition and Collaborates with Diligent for Enhanced Governance Practices

In a significant development poised to shape the future trajectory of corporate governance and risk management, Myriad Genetics has announced a transition in its senior leadership. Effective April 30, 2025, Sam Raha will assume the role of Chief Executive Officer, while Mark S. Verratti steps in as Chief Operating Officer. This strategic shift highlights the company’s commitment to innovation and excellence as it navigates the complexities of the healthcare landscape.This leadership change at Myriad Genetics comes at a time of noteworthy transformation within the realm of governance, risk, and compliance (GRC). The necessity for effective governance frameworks has never been more pronounced, with companies increasingly seeking advanced solutions that can adeptly manage risks while ensuring compliance with an ever-expanding array of regulations. Diligent, a key player in GRC solutions, has been actively pursuing innovations in this sector, recently drawing attention for its comprehensive software-as-a-service (SaaS) offerings.

Financial Statements
Myriad Genetics Inc 's Assets	$ 642 million	MYGN's Balance sheet
Myriad Genetics Inc 's Income	$ -43 million	Quarterly MYGN's Income Statement
MYGN's Income by Division		See MYGN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-27.39 %	-10.44 %	-1.07 %	-11.47 %	-7.32 %
Total Assets in million	707	973	1,087	1,098	1,241
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-366	-127	-263	-112	-27
Annual Return On Assets	-51.78 %	-13.08 %	-24.23 %	-10.2 %	-2.19 %

MYGN's 5 Years Annual ROA >> Back to MYGN Management Effectiveness >> Compare MYGN ROA to its Competitors

More Return On Assets Ratios
MYGN's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MYGN's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MYGN's Competitors
Subscribers only: Roa for Myriad Genetics Inc 's Suppliers
Subscribers only: Return On Assets for MYGN's Customers

You may also want to know
MYGN's Roi	MYGN's Inventory Turnover Ratio	MYGN's Growth Rates	MYGN's Dividend Comparisons
	MYGN's Profitability Ratios	MYGN's Asset Turnover Ratio	MYGN's Dividend Growth
MYGN's Roe	MYGN's Valuation Ratios	MYGN's Financial Strength Ratios	MYGN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T06:55:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.